WNT16 and cancer: Immunohistochemical scores for the NF‐κB downstream target gene WNT16 followed a similar pattern: cisplatin increased WNT16 (P = 6.2 × 10−6 vs. the cancer‐positive group) and the combination therapy reduced it (P = 0.0001 cisplatin vs. cisplatin plus DMAPT) (Fig. 2T–W).